Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high and low baseline viral loads

HIV Clinical Trials

Volumn 2, Issue 4, 2001, Pages 317-322

  Raffi, F ^a   Reliquet, V ^a   Podzamczer, D ^a   Pollard, R B ^a  

^a HÔTEL DIEU   (France)

Author keywords

HAART; Nevirapine; Viral load

Indexed keywords

DIDANOSINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

EID: 0034892588     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/DNVE-H4RG-6FPP-R9RQ     Document Type: Article

References (20)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
3. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial
4. The Atlantic study: A randomized, open-label study to evaluate the efficacy and safety of three triple-combination therapies aimed at different HIV targets in antiretroviral naive HIV-1 infected patients
5. Preliminary results of a randomized multicenter study comparing Combivir (ZDV/3TC) plus nelfinavir or nevirapine in HIV-infected naive patients
6. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease
7. Comparison of antiviral response with abacavir/Combivir to indinavir/Combivir in therapy-naive adults at 48 weeks (CNA3005)
8. d4T + qd ddl + nevirapine (bid or qd) in antiretroviral-naive HIV-1 infected patients: 1-year results of the VIRGO study
9. The VIRGO study: Nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1 infected adults
10. Combination therapy with nevirapine in antiretroviral naive patients is effective in patients with high baseline viral load
11. The durability of virological response in individuals with high viral load to non-nucleoside reverse transcriptase inhibitor therapy
12. 1090 Team. Factors predictive of durable HIV suppression in a randomized double blind trial with nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) in treatment-naive (ARV-n) patients with advanced AIDS
13. Early results of combined stavudine, lamivudine, and nevirapine: A twice daily, well-tolerated, protease inhibitor-sparing regimen for the treatment of HIV-1 infection
14. The efficacy of nevirapine at low versus high viral loads
15. Viral load suppression of highly active antiretroviral therapy (HAART) correlates with baseline CD4+ cell count, but not with viral load
16. Meta-analysis of the effectiveness of triple-combination therapy in antiretroviral naive HIV-1 infected adults
17. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load
18. Nevirapine-containing potent antiretroviral therapy results in an antiatherogenic plasma lipid profile: Results from the Atlantic study
19. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
20. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA